Redmile Group, LLC Stoke Therapeutics, Inc. Transaction History
Redmile Group, LLC
- $822 Million
- Q2 2025
A detailed history of Redmile Group, LLC transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Redmile Group, LLC holds 4,375,931 shares of STOK stock, worth $59.2 Million. This represents 6.04% of its overall portfolio holdings.
Number of Shares
4,375,931
Previous 4,485,981
2.45%
Holding current value
$59.2 Million
Previous $29.8 Million
66.49%
% of portfolio
6.04%
Previous 3.13%
Shares
24 transactions
Others Institutions Holding STOK
# of Institutions
139Shares Held
57.6MCall Options Held
2.7KPut Options Held
57.4K-
Black Rock Inc. New York, NY5.41MShares$73.2 Million0.0% of portfolio
-
Lynx1 Capital Management LP San Juan, PR5.4MShares$73.1 Million18.16% of portfolio
-
Rtw Investments, LP New York, NY5.12MShares$69.3 Million0.89% of portfolio
-
Baker Bros. Advisors LP New York, NY4.63MShares$62.7 Million0.53% of portfolio
-
Morgan Stanley New York, NY3.57MShares$48.4 Million0.0% of portfolio
About Stoke Therapeutics, Inc.
- Ticker STOK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,419,300
- Market Cap $533M
- Description
- Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...